Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes

PF. Halloran, KS. Madill-Thomsen, S. Pon, MLN. Sikosana, GA. Böhmig, J. Bromberg, G. Einecke, F. Eskandary, G. Gupta, LG. Hidalgo, M. Myslak, O. Viklicky, A. Perkowska-Ptasinska, INTERCOMEX Investigators

. 2022 ; 22 (8) : 1976-1991. [pub] 20220602

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024955

We studied the clinical, histologic, and molecular features distinguishing DSA-negative from DSA-positive molecularly defined antibody-mediated rejection (mABMR). We analyzed mABMR biopsies with available DSA assessments from the INTERCOMEX study: 148 DSA-negative versus 248 DSA-positive, compared with 864 no rejection (excluding TCMR and Mixed). DSA-positivity varied with mABMR stage: early-stage (EABMR) 56%; fully developed (FABMR) 70%; and late-stage (LABMR) 58%. DSA-negative patients with mABMR were usually sensitized, 60% being HLA antibody-positive. Compared with DSA-positive mABMR, DSA-negative mABMR was more often C4d-negative; earlier by 1.5 years (average 2.4 vs. 3.9 years); and had lower ABMR activity and earlier stage in molecular and histology features. However, the top ABMR-associated transcripts were identical in DSA-negative versus DSA-positive mABMR, for example, NK-associated (e.g., KLRD1 and GZMB) and IFNG-inducible (e.g., PLA1A). Genome-wide class comparison between DSA-negative and DSA-positive mABMR showed no significant differences in transcript expression except those related to lower intensity and earlier time of DSA-negative ABMR. Three-year graft loss in DSA-negative mABMR was the same as DSA-positive mABMR, even after adjusting for ABMR stage. Thus, compared with DSA-positive mABMR, DSA-negative mABMR is on average earlier, less active, and more often C4d-negative but has similar graft loss, and genome-wide analysis suggests that it involves the same mechanisms. SUMMARY SENTENCE: In 398 kidney transplant biopsies with molecular antibody-mediated rejection, the 150 DSA-negative cases are earlier, less intense, and mostly C4d-negative, but use identical molecular mechanisms and have the same risk of graft loss as the 248 DSA-positive cases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024955
003      
CZ-PrNML
005      
20221031101340.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ajt.17092 $2 doi
035    __
$a (PubMed)35575435
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Halloran, Philip F $u Alberta Transplant Applied Genomics Centre, Edmonton, Alberta, Canada $u Department of Medicine, Division of Nephrology and Transplant Immunology, University of Alberta, Edmonton, Alberta, Canada $1 https://orcid.org/0000000313711947
245    10
$a Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes / $c PF. Halloran, KS. Madill-Thomsen, S. Pon, MLN. Sikosana, GA. Böhmig, J. Bromberg, G. Einecke, F. Eskandary, G. Gupta, LG. Hidalgo, M. Myslak, O. Viklicky, A. Perkowska-Ptasinska, INTERCOMEX Investigators
520    9_
$a We studied the clinical, histologic, and molecular features distinguishing DSA-negative from DSA-positive molecularly defined antibody-mediated rejection (mABMR). We analyzed mABMR biopsies with available DSA assessments from the INTERCOMEX study: 148 DSA-negative versus 248 DSA-positive, compared with 864 no rejection (excluding TCMR and Mixed). DSA-positivity varied with mABMR stage: early-stage (EABMR) 56%; fully developed (FABMR) 70%; and late-stage (LABMR) 58%. DSA-negative patients with mABMR were usually sensitized, 60% being HLA antibody-positive. Compared with DSA-positive mABMR, DSA-negative mABMR was more often C4d-negative; earlier by 1.5 years (average 2.4 vs. 3.9 years); and had lower ABMR activity and earlier stage in molecular and histology features. However, the top ABMR-associated transcripts were identical in DSA-negative versus DSA-positive mABMR, for example, NK-associated (e.g., KLRD1 and GZMB) and IFNG-inducible (e.g., PLA1A). Genome-wide class comparison between DSA-negative and DSA-positive mABMR showed no significant differences in transcript expression except those related to lower intensity and earlier time of DSA-negative ABMR. Three-year graft loss in DSA-negative mABMR was the same as DSA-positive mABMR, even after adjusting for ABMR stage. Thus, compared with DSA-positive mABMR, DSA-negative mABMR is on average earlier, less active, and more often C4d-negative but has similar graft loss, and genome-wide analysis suggests that it involves the same mechanisms. SUMMARY SENTENCE: In 398 kidney transplant biopsies with molecular antibody-mediated rejection, the 150 DSA-negative cases are earlier, less intense, and mostly C4d-negative, but use identical molecular mechanisms and have the same risk of graft loss as the 248 DSA-positive cases.
650    _2
$a protilátky $7 D000906
650    _2
$a biopsie $7 D001706
650    _2
$a rejekce štěpu $x diagnóza $x etiologie $7 D006084
650    _2
$a lidé $7 D006801
650    _2
$a isoprotilátky $7 D007518
650    12
$a transplantace ledvin $x škodlivé účinky $7 D016030
650    _2
$a dárci tkání $7 D014019
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Madill-Thomsen, Katelynn S $u Alberta Transplant Applied Genomics Centre, Edmonton, Alberta, Canada
700    1_
$a Pon, Shane $u Alberta Transplant Applied Genomics Centre, Edmonton, Alberta, Canada
700    1_
$a Sikosana, Majid L N $u Alberta Transplant Applied Genomics Centre, Edmonton, Alberta, Canada
700    1_
$a Böhmig, Georg A $u Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/000000027600912X
700    1_
$a Bromberg, Jonathan $u University of Maryland, Baltimore, Maryland, USA
700    1_
$a Einecke, Gunilla $u Department of Nephrology, Hannover Medical School, Hannover, Germany
700    1_
$a Eskandary, Farsad $u Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria
700    1_
$a Gupta, Gaurav $u Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA $1 https://orcid.org/0000000319191970
700    1_
$a Hidalgo, Luis G $u University of Wisconsin, Madison, Wisconsin, USA
700    1_
$a Myslak, Marek $u Department of Clinical Interventions, Department of Nephrology and Kidney Transplantation SPWSZ Hospital, Pomeranian Medical University, Szczecin, Poland
700    1_
$a Viklicky, Ondrej $u Department of Nephrology and Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic $1 https://orcid.org/0000000310492195
700    1_
$a Perkowska-Ptasinska, Agnieszka $u Department of Pathology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000155243534
710    2_
$a INTERCOMEX Investigators
773    0_
$w MED00006447 $t American journal of transplantation $x 1600-6143 $g Roč. 22, č. 8 (2022), s. 1976-1991
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35575435 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031101338 $b ABA008
999    __
$a ok $b bmc $g 1854580 $s 1176245
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 22 $c 8 $d 1976-1991 $e 20220602 $i 1600-6143 $m American journal of transplantation $n Am J Transplant $x MED00006447
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace